All eterna therapeutics articles
-
ArticleEpisode 24 - Genetic engineering for allogeneic immunotherapy
Listen to this podcast where we dive into genetic engineering, its role and relationship with allogeneic immunotherapy.
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.